HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.

Platelet-Activating Factor Induces Epigenetic Modifications in Human Mast Cells. J Invest Dermatol (2015) 0.82

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget (2016) 0.78

Identification and characterization of PKF118-310 as a KDM4A inhibitor. Epigenetics (2016) 0.77

Expression of LOC285758, a Potential Long Non-coding Biomarker, is Methylation-dependent and Correlates with Glioma Malignancy Grade. Radiol Oncol (2017) 0.75

Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19

TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res (2006) 22.20

A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics (2001) 16.47

MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res (2003) 11.82

Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics (2005) 10.64

An operational definition of epigenetics. Genes Dev (2009) 4.26

Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol (2008) 3.56

Genome-wide binding map of the histone deacetylase Rpd3 in yeast. Nat Genet (2002) 3.18

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 2.66

Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther (2009) 2.50

Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev (2010) 2.14

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood (2004) 2.13

Histone deacetylases--an important class of cellular regulators with a variety of functions. Appl Microbiol Biotechnol (2007) 1.65

Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J Neurosci (2009) 1.58

Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther (2007) 1.50

Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J (2010) 1.47

Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A (2009) 1.46

Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol (2004) 1.40

Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem (2010) 1.33

A personalized approach to cancer treatment: how biomarkers can help. Clin Chem (2008) 1.25

Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A (1989) 1.20

Trials with 'epigenetic' drugs: an update. Mol Oncol (2012) 1.19

HDAC2: a critical factor in health and disease. Trends Pharmacol Sci (2009) 1.15

A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics (2008) 1.14

Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression. Proc Natl Acad Sci U S A (2005) 1.08

AML in older patients: are we making progress? Best Pract Res Clin Haematol (2009) 1.08

Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05

It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res (2005) 1.02

Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res (2008) 0.97

CIITA and Its Dual Roles in MHC Gene Transcription. Front Immunol (2013) 0.95

An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res Treat (2011) 0.93

DNA damage in the presence of chemical genotoxic agents induce acetylation of H3K56 and H4K16 but not H3K9 in mammalian cells. Mol Biol Rep (2011) 0.89

Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal (2014) 0.88

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget (2014) 0.87

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology (2013) 0.86

The anticancer effects of HDAC inhibitors require the immune system. Oncoimmunology (2014) 0.85

New drugs in acute myeloid leukemia. Semin Oncol (2008) 0.85

CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells. Int J Cancer (2012) 0.83

Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leuk Res (2003) 0.81

Functions, aberrations, and advances for chromatin modulation in cancer. Cancer Treat Res (2014) 0.80